The icy IPO market for biotech may be thawing slightly, with two companies—Apogee Therapeutics and Sagimet Biosciences—revealing their pricing plans for going public.

两家公司Apogee Therapeutics和Sagimet Biosciences透露了他们上市的定价计划，生物技术的冰冷IPO市场可能会略有融化。

Apogee, the first spinout from Paragon Therapeutics, launched at the end of 2022 with a sizable $169 million on hand. The inflammatory and immune-focused biotech quickly set its sights on the public markets, announcing in June plans to list on the Nasdaq.

Apogee是Paragon Therapeutics的第一批脱颖而出产品，于2022年底推出，手头拥有1.69亿美元。这种以炎症和免疫为重点的生物技术很快就将视线推向了公共市场，6月份宣布计划在纳斯达克上市。

The biotech has now revealed an expected public offering of around $228 million, according to Securities and Exchange Commission documents filed July 10. The figure is based on an assumed offering price of $16 per share for 15.6 million shares of common stock. The offering could reach $263 million if underwriters fully exercise their option to buy additional shares of common stock..

根据7月10日提交的证券交易委员会文件，该生物技术公司现已公布预计公开发行约2.28亿美元。该数字基于假定的报价 $每股16股，共1560万股普通股。如果承销商充分行使购买额外普通股股份的期权，该股票可达到2.63亿美元。。

The biotech appears to be living up to its namesake—Apogee, which means the highest point in the development of something. In an almost year-long stretch of frozen IPO conditions for biotech, with only a handful of companies debuting on the market in 2023, the young biotech is charging ahead.

生物技术似乎正处于同名的顶峰，这意味着某些事物发展的最高点。在生物技术公司近一年的冷冻IPO条件下，只有少数公司在2023年上市，young biotech正在领先。

Apogee plans to use the proceeds from the offering to fund clinical trials, manufacturing programs and preclinical research. The company’s lead candidate is a monoclonal antibody, dubbed APG777, that Apogee is touting as a potential rival to Dupixent. Like Regeneron and Sanofi’s blockbuster, the asset is designed to inhibit IL-13 signaling, although Dupixent also inhibits IL-4 signaling.

Apogee计划使用提供的收益来资助临床试验，制造计划和临床前研究。该公司的主要候选人是一种名为APG777的单克隆抗体，Apogee被吹捧为Dupixent的潜在竞争对手。像Regeneron和赛诺菲的重磅炸弹一样，asset旨在抑制IL-13信号传导，尽管Dupixent也抑制IL-4信号传导。

In preclinical studies, APG777 has demonstrated “equivalent or superior” IL-13 inhibition than Eli Lilly’s investigational therapy lebrikizumab—another IL-13 drug, according to Apogee..

根据Apogee的研究，在临床前研究中，APG777已证明与礼来公司的研究疗法lebrikizumab（另一种IL-13药物）相比，IL-13抑制作用“等效或优越”。。

The biotech expects to investigate APG777 in similar indications to Dupixent and lebrikizumab, namely atopic dermatitis and asthma. A phase 1 trial in healthy volunteers is planned in Australia for the second half of this year, which is designed to set up phase 2 and 3 studies in atopic dermatitis.

该生物技术公司希望以与Dupixent和lebrikizumab类似的适应症研究APG777，即特应性皮炎和哮喘。今年下半年，澳大利亚计划在健康志愿者中进行第一阶段试验，旨在建立特应性皮炎的第二阶段和第三阶段研究。

At the same time, San Mateo, California-based Sagimet has also shared expected pricing info for its IPO: $66.3 million for 4.68 million shares of series A common stock. Using an approximate price of $16 per share, the liver disease and cancer company said the offering could reach $76.7 million if underwriters exercise their option to purchase additional shares in full..

与此同时，位于加利福尼亚州圣马特奥的Sagimet也分享了其IPO的预期定价信息：6630万美元，其中468万股A系列普通股股票。肝病和癌症公司以每股16美元的近似价格表示，如果承销商行使完全购买额外股份的选择权，该报价可能达到7670万美元。。

The company had actually planned to hit the markets in 2021 with a $75 million offering—a time when biotech IPOs flourished—but backed away in early 2022 as the market started to ice over.

该公司实际上计划在2021年以7500万美元的报价进入市场-这是生物技术首次公开发行，但随着市场开始停滞不前，于2022年初退出市场。

Sagiment plans to use the potential $66 million to further development of denifanstat, or TVB-2640, an oral, once-daily pill that is being evaluated in a phase 2b trial for patients with non-alcoholic steatohepatitis. The company also hopes to use the money to launch a pivotal phase 3 trial for the program in the same indication..

Sagiment计划利用潜在的6600万美元进一步开发denifanstat或TVB-2640，这是一种口服，每日一次的药丸，正在2b期试验中对非酒精性脂肪性肝炎患者进行评估。该公司还希望用这些钱为该计划启动关键的3期试验。。